Skip to main content
. Author manuscript; available in PMC: 2014 Sep 1.
Published in final edited form as: Biol Psychiatry. 2013 May 15;74(5):348–356. doi: 10.1016/j.biopsych.2013.04.009

Figure 5.

Figure 5

Genetic absence and pharmacologic inhibition of 5-lipoxygenase activating protein (FLAP) ameliorates synaptic biomarkers and decreases neuroinflammation in triple transgenic (3×Tg) mice. (A) Representative Western blot analyses for synaptophysin (SYP), postsynaptic density protein 95 (PSD95), and microtubule associated protein-2 (MAP-2) in brain homogenates from cortices of wildtype and 3×Tg mice and mice genetically deficient for FLAP (3×Tg-FLAPKO). (B) Densitometric analyses of the immunoreactivities from panel A (*p < .001). (C) Representative immunohistochemical stainings in hippocampus for SYP-, PSD95-, and MAP-2-positive areas in brain sections of 3×Tg and 3×Tg-FLAPKO mice. (D) Representative Western blot analyses for SYP, PSD95, and MAP-2 in brain homogenates from cortices of wildtype, 3×Tg, and 3×Tg-MK-591 mice. (E) Densitometric analyses of the immunoreactivities from panel D (*p < .001). (F) Representative immunohistochemical stainings in hippocampus for SYP-, PSD95-, and MAP-2-positive areas in brain sections of 3×Tg and 3×Tg-MK-591 mice. (G) Representative Western blot analyses for glial fibrillary acidic protein (GFAP) and custer domain (CD)45 in brain homogenates from 3×Tg and 3×Tg-FLAPKO mice. (H) Densitometric analyses of the immunoreactivities to the antibodies from the previous panel (3×Tg, n = 4; 3×Tg-FLAPKO, n = 4; *p < .001). (I) Representative Western blot analyses for GFAP and CD45 in brain homogenates from 3×Tg and 3×Tg-MK-591 mice. (J) Densitometric analyses of the immunoreactivities to the antibodies from the previous panel (3×Tg, n = 4; 3×Tg-MK-591, n = 4; *p < .01). Values represent mean ± SEM.